Business
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
Enters Licensing Agreement with UNeMed Corporation (UNeMed), the Technology Transfer Office of University of Nebraska Medical Center Abundant evidence
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\nEnters Licensing Agreement with UNeMed Corporation (UNeMed), the Technology Transfer Office of University of Nebraska Medical Center\n\n\n\nAbundant evidence indicates that high levels of inflammation and decreased levels of Regulatory T cells (Tregs) lead to an increased oxidative state in PD, which play a major role in disease progression and possibly etiology\n\n\n\n\nCOYA 301 is a low-dose-IL-2 (ld IL-2) formulation for subcutaneous administration, intended to enhance Treg function in vivo to treat the systemic and neuro-inflammation underlying neurodegenerative and autoimmune diseases\n\n\n\n\nThis agreement grants Coya the exclusive license to patent rights and know-how (IP) related to COYA 301 and combinations for treatment of PD\n\n\n\n\nIP is based on recently published data documenting that ld IL-2 significantly expands Treg populations and protects nigrostriatal dopaminergic neurons in an animal model of PD\n\n\n\n\nThe license further diversifies Coya’s Treg enhancing biologic portfolio in neurodegenerative disease and expands upon the promising clinical data recently presented in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) while opening strategic clinical partnering opportunities in PD\n\n\n\n \n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, today announced expansion of its patent estate for COYA 301, the Company’s low-dose IL-2 (ld IL-2) subcutaneous administration product candidate. Under the terms of the agreement with UNeMed, Coya has been granted the exclusive patent rights and know-how for use of ld IL-2 and ld IL-2 combinations for PD. UNeMed will receive payments upon achievement of certain milestones and will also be eligible to receive tiered low-single digit royalty on net sales.\n\n\n“We believe that Treg dysfunction is the common thread that binds together many neurodegenerative diseases. This license is based on strong preclinical animal data in PD, builds upon the highly promising clinical data observed in ALS and AD, and expands the optionality that Coya has in strategic partnering discussions to execute on future clinical trials in PD,” said Arun Swaminathan, Ph.D., Chief Business Officer.\n\n\nThe preclinical mo...